<table class="naaccr-summary-table naaccr-borders">
    <tr>
        <th class="naaccr-summary-header naaccr-borders">Item #</th>
        <th class="naaccr-summary-header naaccr-borders">Length</th>
        <th class="naaccr-summary-header naaccr-borders">Source of Standard</th>
        <th class="naaccr-summary-header naaccr-borders">Year Implemented</th>
        <th class="naaccr-summary-header naaccr-borders">Version Implemented</th>
        <th class="naaccr-summary-header naaccr-borders">Year Retired</th>
        <th class="naaccr-summary-header naaccr-borders">Version Retired</th>
        <th class="naaccr-summary-header naaccr-borders">Column #</th>
    </tr>
    <tr>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">940</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">4</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">AJCC</td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered"></td>
        <td class="naaccr-summary-cell naaccr-borders naaccr-summary-centered">1065 - 1068</td>
    </tr>
</table>

<br/><strong>NAACCR XML</strong>: Tumor.tnmClinT<br/><br/>
<strong>Alternate Names</strong>
<br/>&nbsp;&nbsp;&nbsp;Clinical T (CoC)


<div class='content chap10-para-head'><strong><strong>Description</strong></strong></div>
<div class='content chap10-para'>Detailed site-specific codes for the clinical tumor (T) as defined by AJCC and recorded by the physician.<br/><br/>Pathologic and clinical stage data are given three separate areas in the NAACCR Data Exchange Record Layout.
</div>
<div class='content chap10-para-head'><strong><strong>Rationale</strong></strong></div>
<div class='content chap10-para'>CoC requires that AJCC TNM staging be used in its approved cancer programs. AJCC developed its staging system for evaluating trends in the treatment and control of cancer. This staging is used by physicians to estimate prognosis, to plan treatment, to evaluate new types of therapy, to analyze outcome, to design follow-up strategies, and to assess early detection results.</div>
<div class='content chap10-para'><strong>Codes (in addition to those published in the <em>AJCC Cancer Staging Manual</em>)</strong></div>
<div class='content chap10-para'>
    <table>
        <tr class='code-row'>
            <td class='code-nbr'>88</td>
            <td class='code-desc'>Not applicable, no code assigned for this case in the current AJCC Staging Manual.</td>
        </tr>
        <tr class='code-row'>
            <td class='code-nbr' colspan='2'>This field is left blank if no information at all is available to code this item.</td>
        </tr>
    </table>
</div>
<div class='content chap10-para mark-changed'>
    <em>Note:</em> See the<em> AJCC Cancer Staging Manual</em>, current edition for site-specific categories for the TNM elements and stage groups. See the<em> STORE </em>manual for specifications for codes and data entry rules.
</div>